Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Progesterone receptor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    265 result(s) found for: Progesterone receptor. Displaying page 7 of 14.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2008-003064-19 Sponsor Protocol Number: NeoTEC Start Date*: 2008-12-30
    Sponsor Name:Universität Leipzig
    Full Title: Phase-IIb-Study to Evaluate the Effect of a Neoadjuvant Chemotherapy with Docetaxel, Epirubicine and Cyclphosphamide (TEC) in Patients with primary HER-2 neu Negative Mammacarcinoma
    Medical condition: Primary mamma carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002123-15 Sponsor Protocol Number: GEICAM/2019-01 Start Date*: 2020-06-15
    Sponsor Name:GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)
    Full Title: Phase II, randomized, open-label, international, multicenter study to compare efficacy of standard chemotherapy vs. letrozole plus abemaciclib as neoadjuvant therapy in HR-positive/HER2-negative hi...
    Medical condition: High/intermediate risk hormone receptor (HR) positive/human epidermal growth factor receptor 2 (HER2) negative breast cancer patients with indication of neoadjuvant therapy
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001779-54 Sponsor Protocol Number: GEICAM/2015-04 Start Date*: 2017-01-05
    Sponsor Name:GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)
    Full Title: A multicenter phase II trial to evaluate the efficacy and safety of pembrolizumab and gemcitabine in patients with HER2-negative Advanced Breast Cancer (ABC). “PANGEA-Breast”
    Medical condition: Patients with HER2-negative advanced breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-003320-30 Sponsor Protocol Number: D2270C00020 Start Date*: 2016-01-05
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase I/II Multicenter Study of the Combination of AZD2014 and Palbociclib on a background of Hormonal Therapy in Patients with Locally Advanced/Metastatic Estrogen Receptor Positive Breast Cance...
    Medical condition: Locally advanced or metastatic estrogen receptor positive breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2014-003798-41 Sponsor Protocol Number: GIM18-FUMANCE Start Date*: 2015-07-02
    Sponsor Name:CONSORZIO ONCOTECH
    Full Title: Randomized phase III study of fulvestrant as maintenance therapy after first-line chemotherapy in HER2 negative postmenopausal metastatic breast cancer patients
    Medical condition: Women with HR+, HER2- metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-004391-35 Sponsor Protocol Number: NSABP-FB7 Start Date*: 2014-02-18
    Sponsor Name:Puma Biotechnology Inc.
    Full Title: A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens with Weekly Paclitaxel plus Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophosp...
    Medical condition: Locally advanced HER2-positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed) ES (Completed) PT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002230-32 Sponsor Protocol Number: WO29479 Start Date*: 2014-12-18
    Sponsor Name:F. Hoffman-La Roche Ltd., realizado en España por Roche Farma S.A.
    Full Title: A MULTISTAGE, PHASE II, STUDY EVALUATING THE SAFETY AND EFFICACY OF COBIMETINIB IN COMBINATION WITH PACLITAXEL AS FIRST-LINE TREATMENT FOR PATIENTS WITH METASTATIC TRIPLE-NEGATIVE BREAST CANCER
    Medical condition: Patients with metastatic or locally advanced, triple-negative adenocarcinoma of the breast that have not received prior systemic therapy for metastatic breast cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) BE (Completed) FR (Completed) LT (Completed) LV (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002893-11 Sponsor Protocol Number: PASIPHAE Start Date*: 2017-08-14
    Sponsor Name:Karolinska University Hospital
    Full Title: A phase 2, international, multicenter, open-labeled, randomized trial of PAlbociclib and fulvestrant vs. Standard oral capecitabine In Patients with Hormone receptor positive/HER2 negative Advanced...
    Medical condition: Hormone receptor positive/HER2 negative advanced breast cancer with endocrine resistance
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-002872-42 Sponsor Protocol Number: PUMA-NER-5201 Start Date*: 2014-03-25
    Sponsor Name:Puma Biotechnology, Inc
    Full Title: An Open-Label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR gene amplification
    Medical condition: Cancer tumor with somatic human epidermal growth factor receptor mutation (EGFR, ERBB2 (HER2), ERBB3 (HER3) or EGFR gene amplification
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10065143 Malignant solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) FI (Completed) GB (GB - no longer in EU/EEA) DK (Completed) BE (Completed) FR (Ongoing) IE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004466-26 Sponsor Protocol Number: G1T28-04 Start Date*: 2017-07-10
    Sponsor Name:G1 Therapeutics
    Full Title: Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients with Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy
    Medical condition: Locally recurrent or metastatic Triple Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) SI (Completed) HR (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2021-001398-22 Sponsor Protocol Number: SOLTI-1910 Start Date*: 2021-12-28
    Sponsor Name:SOLTI
    Full Title: Predicting olaparib sensitivity in patients with unresectable locally advanced/metastatic HER2-negative breast cancer with BRCA1, BRCA2, PALB2, RAD51C or RAD51D mutations or RAD51-foci low test: RA...
    Medical condition: Pre and post-menopausal women and men with unresectable locally advanced or metastatic triple negative breast cancer (TNBC) or ET ±CDK4/6-resistant hormonal receptor positive and HER2-negative (HR+...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000579-12 Sponsor Protocol Number: D4200L00009 Start Date*: 2008-12-03
    Sponsor Name:ASTRAZENECA
    Full Title: A randomised, double-blind, parallel-group, multicentre, phase ii study to evaluate the safety and pharmacological activity of the combination of Vandetanib (100 or 300 mg/daily or placebo) with Fu...
    Medical condition: Postmenopausal women with advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000284-17 Sponsor Protocol Number: VinoMetro2015-007 Start Date*: 2016-11-11
    Sponsor Name:Universitätsmedizin Mainz
    Full Title: Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2- breast cancer resistant to endocrine therapy (VinoMetro).
    Medical condition: HR+/HER2- advanced/metastatic breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001421-13 Sponsor Protocol Number: AGMT_MBC-10(X16087) Start Date*: 2016-08-31
    Sponsor Name:AGMT gGmbH
    Full Title: Ixazomib (MLN9708) in combination with carboplatin in pretreated women with advanced triple negative breast cancer (CARIXA)
    Medical condition: Advanced (locally advanced inoperable or metastatic) triple negative breast cancer progressing after first-line therapy
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003575-18 Sponsor Protocol Number: ICO-2020-06 Start Date*: 2020-12-08
    Sponsor Name:INSTITUT DE CANCEROLOGIE DE L'OUEST
    Full Title: Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ
    Medical condition: Patients with extensive ductal carcinoma in situ with an indication for total mastectomy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006189 Breast cancer in situ PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-001902-14 Sponsor Protocol Number: D5760C00001 Start Date*: 2017-11-06
    Sponsor Name:MedImmune LLC, a wholly owned subsidiary of AstraZeneca PLC
    Full Title: A Phase 1/2 Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI4276 in Subjects with Select H...
    Medical condition: HER2 expressing Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066896 HER-2 positive gastric cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    20.0 100000016800 10066354 Adenocarcinoma of the gastroesophageal junction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000367-98 Sponsor Protocol Number: TRA100773 Start Date*: 2005-02-11
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A double-blind, randomised, placebo-controlled, parallel group study to investigate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of SB-497115-GR, a thrombopoietin recep...
    Medical condition: Immune thrombocytopenic purpura (ITP)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed) EE (Completed) LV (Completed) IE (Completed) DK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-005548-27 Sponsor Protocol Number: I3Y-MC-JPBN Start Date*: 2014-05-16
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2 Study of LY2835219 for Patients with Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-003906-26 Sponsor Protocol Number: ZEN003694-004 Start Date*: 2019-08-22
    Sponsor Name:Zenith Epigenetics Ltd.
    Full Title: A Phase 2 Study of ZEN003694 in Combination with Talazoparib in Patients with Triple-Negative Breast Cancer
    Medical condition: Triple Negative Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10071115 Node-negative breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-004513-27 Sponsor Protocol Number: MedOPP127 Start Date*: 2017-09-04
    Sponsor Name:Medica Scientia Innovation Research (MedSIR)
    Full Title: A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes
    Medical condition: Hormone receptor-(HR)positive/HER2-negative metastatic breast cancer (MBC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000020826 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 17 11:16:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA